1 05, 2023

Will Protalix BioTherapeutics Keep Powering Higher After its 178% Run Up Since November 2022?

By |2023-12-07T20:56:34+00:00May 1st, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , |

Protalix BioTherapeutics, Inc. (PLX: NYSE AMEX and Tel Aviv Stock Exchange) is headquartered in Carmiel, Israel with an office in Hackensack, NJ, with a total of 197 employees. Protalix Ltd. was incorporated in 1993. It became a U.S public company on December 31, 2006. PLX is a biopharmaceutical company that develops, produces and commercializes [...]

18 04, 2023

Amneal Pharma Issues Guidance Over Market Forecasts, But We See 3 Things Holding the Stock Back

By |2023-12-07T20:57:13+00:00April 18th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , |

Yesterday, Amneal Pharmaceuticals (AMRX) issued guidance for the first quarter of 2023 that came in over the consensus estimates. This sent shares trading as much as 14% higher in premarket trading. The stock opened Monday’s trading session at $1.34/share and closed at $1.63 for a nice single-day gain. The pharmaceutical company says that revenue [...]

14 04, 2023

Why is UnitedHealth Falling After Beating Earnings Expectations and Raising Guidance?

By |2023-12-07T20:57:23+00:00April 14th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , |

This morning, UnitedHealth Group (UNH) reported first-quarter earnings that came in over expectations. The company doubled down on this success, raising the full-year outlook for 2023. And yet, shares of the company are falling - down nearly 3% in Friday’s trading session so far. This has investors and the market as a whole perplexed. [...]

11 04, 2023

Is Pfizer’s RSV Vaccine Advancements Enough to Earn the Stock a Buy?

By |2023-12-07T20:57:52+00:00April 11th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , |

Pfizer (PFE) has climbed more than 2% in this shortened trading week, and this could be due to the recent advancements in their latest vaccine. The RSV (respiratory syncytial virus) vaccine has been found to be 82% effective in preventing a respiratory virus in infants. The way the vaccine works is through administration to [...]

10 04, 2023

Is Elevance Health, Inc. Ready to Rebound to its October 31, 2022 All- Time High?

By |2023-12-07T20:57:57+00:00April 10th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , |

Elevance Health, Inc., (ELV:NYSE), founded in 1944 is based in Indianapolis.  It is a health benefits provider that supports health at each life stage, providing health plans and clinical, behavioral, pharmacy, and complex-care solutions that promote members' whole health. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, [...]

28 03, 2023

Moderna Deal Sends Generation Bio Shares 34% Higher…Should You Take a Chance on This Stock?

By |2023-12-07T20:58:18+00:00March 28th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , |

Last week Moderna (MRNA) announced a licensing deal with Generation Bio that they hope will allow them to overcome the losses they’re facing now that the COVID-19 pandemic has come and gone. And as a result of this deal, Generation Bio (GBIO) gained 34% in the past week of trading. The partnership will have [...]

6 03, 2023

Why DexCom Fell 8% Monday Morning and What Investors Should Do About This Stock

By |2023-12-07T20:59:36+00:00March 6th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , |

Monday morning’s trading session was not a pleasant one for DexCom (DXCM) or its investors. Shares of the medical device manufacturing company fell 8% by 12PM EST with no signs of slowing down. But what happened to cause this slip? It wasn’t necessarily anything DexCom did or didn’t do. Rather, close competitor Abbott Laboratories [...]

3 03, 2023

Lantheus Holdings, Inc. Bolts 21% Higher on Year-Over-Year Triple Digit Revenue Growth

By |2023-12-07T20:59:40+00:00March 3rd, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , |

Last week, the stock market had its worst week in 2023 down about 2-3% depending upon the index selected, but Lantheus Holdings, Inc. (Nasdaq:LNTH) stock price jumped 21.3%. That was because its worldwide revenues for the fourth quarter and full year 2022, accelerated 103.1% and 119.9%, respectively, over prior year periods. Although not a [...]

27 02, 2023

Seagen Jumps 11% on Pfizer Acquisition Rumors – Should You Buy the Hype Early?

By |2023-12-07T21:00:34+00:00February 27th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , |

As Pfizer’s sales continue to struggle, they’ve turned to acquisitions as a means of making up for lost revenue. And one company they have their eye on is Seagen - a cancer drugmaker with a market cap of roughly $30 billion. Last year, Seagen was rumored to be acquired by Merck. This deal could [...]

6 02, 2023

Catalent is Up 22% Amidst Acquisition Rumors: Is the Stock Worth a Buy, Though?

By |2023-12-07T21:03:00+00:00February 6th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , |

Catalent (CTLT) is all over the headlines this Monday morning as rumors surge of an acquisition. The buyer in question is Danaher (DHR), a company that designs and manufactures diagnostic tools for health, food, and water services. This play is said to be Danaher’s way of competing with Thermo Fisher Scientific. This marriage makes [...]

Go to Top